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Abstract 
Background: SCLC has limited treatment options and inadequate preclinical models. Promising activity of arsenic tri‑
oxide (ASO) recorded in conventional preclinical models of SCLC supported the clinical evaluation of ASO in patients. 
We assessed the efficacy of ASO in relapsed SCLC patients and in corresponding patient‑derived xenografts (PDX).
Methods: Single arm, Simon 2‑stage, phase II trial to enroll patients with relapsed SCLC who have failed at least one 
line of therapy. ASO was administered as an intravenous infusion over 1–2 h daily for 4 days in week 1 and for 2 days 
in weeks 2–6 of an 8‑week cycle. Treatment continued until disease progression. Pretreatment tumor biopsy was 
employed for PDX generation through direct implantation into subcutaneous pockets of SCID mice without in vitro 
manipulation and serially propagated for five generations. Ex vivo efficacy of cisplatin (3 mg/kg i.p. weekly) and ASO 
(3.75 mg/kg i.p. every other day) was tested in PDX representative of platinum sensitive and platinum refractory SCLC.
Results: The best response in 17 evaluable patients was stable disease in 2 (12 %), progressive disease in 15 (88 %) 
patients and median time‑to‑progression of seven (range 1–7) weeks. PDX was successfully grown in 5 of 9 (56 %) 
transplanted biopsy samples. Serially‑propagated PDXs preserved characteristic small cell histology and genomic 
stability confirmed by immunohistochemistry, short tandem repeat (STR) profiling and targeted sequencing. ASO 
showed in vitro cytotoxicity but lacked in vivo efficacy against SCLC PDX tumor growth.
Conclusions: Cisplatin inhibited growth of PDX derived from platinum‑sensitive SCLC but was ineffective against 
PDX from platinum‑refractory SCLC. Strong concordance between clinical and ex vivo effects of ASO and cisplatin 
in SCLC supports the use of PDX models to prescreen promising anticancer agents prior to clinical testing in SCLC 
patients.
Trial Registration The study was registered at http://www.clinicaltrials.gov (NCT01470248)
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Background
Small cell lung cancer (SCLC) constitutes approxi-
mately 15 % of all cases of lung cancer, which translates 
to 30,000 new cases in the US and almost 200,000 new 
cases worldwide each year [1, 2]. While it is a very che-
mosensitive disease in the frontline setting, the out-
come is dismal with median survival of only 10 months 
and 2-year survival rate as low as 2.2 % [2, 3]. Relapsed 
SCLC is much less responsive to chemotherapy [3–5]. 
The underlying mechanism responsible for the high rate 
of relapse and the poor outcome for relapsed SCLC is 
poorly understood but progressive outgrowth of resist-
ant clones selected by the initial chemotherapy regimen 
is one potential reason. Preclinical data in SCLC cell lines 
revealed the presence of a rare sub-clone with a stem-cell 
phenotype characterized by surface receptor expression 
of CD44, CD133, multi-drug resistance gene (MDR1) and 
urokinase plasminogen activator receptor (uPAR) [6–8]. 
This cell population frequently exhibits primary resist-
ance to frontline chemotherapy agents including cisplatin 
and etoposide [7, 8]. Furthermore, these cells possess a 
high capacity for self-renewal, differentiation into adult 
cancer cells and increased tumorigenesis in clonogenic 
assays.
Targeting this population of cells with differentiat-
ing agents such as arsenic trioxide (ASO) is expected to 
confer clinical benefit especially in relapsed SCLC where 
prior therapies could enrich for this sub-clone of resistant 
undifferentiated cells. Indeed, ASO was shown in several 
preclinical studies to induce potent in  vitro cytotoxicity 
against SCLC through the activation of both necrotic and 
apoptotic cell death pathways in SCLC cell lines [9–11]. 
It also achieved significant tumor growth delay in stand-
ard subcutaneous xenograft models derived from tradi-
tional SCLC cell lines [10–12].
Based on this preclinical data, we designed a phase II 
clinical trial to test the efficacy of ASO as salvage ther-
apy for relapsed SCLC. Because of the repeated failure 
to translate preclinical signal into clinical activity in this 
disease, we also tested the efficacy of ASO ex vivo using 
patient-derived xenografts (PDX) established using 
tumor biopsy samples collected from patients enrolled in 
the study.
Methods
The primary objective of the study was to determine 
the objective response rate (ORR) associated with ASO 
as treatment for relapsed SCLC. Other objectives were 
to determine the progression free survival and overall 
survival associated with single agent ASO in refractory 
SCLC and to correlate the clinical efficacy observed in 
patients with the activity in corresponding PDXs gener-
ated using pretreatment tumor biopsies obtained from 
patients enrolled on study. ASO was generously provided 
by Teva Pharmaceuticals, (North Wales, PA 19454 US). 
All patients were enrolled through the thoracic medical 
oncology clinic of the Winship Cancer Institute of Emory 
University. The study was conducted under a prospec-
tive clinical trial protocol approved by the Emory Uni-
versity Institutional Review Board (IRB00024810). Study 
conduct was in compliance with all ethical standards 
and good clinical practice. All study participants pro-
vided written informed consent prior to undergoing any 
protocol-related procedures. The study was registered at 
http://www.clinicaltrials.gov (NCT01470248).
Eligibility
Adult patients 18 years or older with a pathologic diag-
nosis of SCLC and who progressed following at least one 
line of standard treatment were eligible for the study. 
There was no limit to the number of prior therapies. 
Other salient requirements included measurable disease 
by RECIST criteria, ECOG performance status ≤2, and 
normal organ and marrow function: absolute neutrophil 
count >1500/mL, platelets >100,000/mL, total bilirubin 
≤1.5 X ULN, AST/ALT <2.5 X ULN, creatinine ≤1.5 X 
ULN or creatinine clearance >40  mL/min/1.73  m2. Due 
to the potential for cardiac toxicity with ASO, patients 
with history of QTc prolongation syndrome or any other 
cardiac conduction abnormality evidenced by abnormal 
baseline EKG (QTc ≤450 and ≤470 in males and females, 
respectively) or who required treatment with medication 
with potential to prolong the QT interval or induce Tor-
sade’s de Pointes were excluded. Other pertinent exclu-
sion factors included uncontrolled symptomatic brain 
metastases or intercurrent illness that would limit com-
pliance with study requirements.
Patient selection and treatment administration
Patients were entered into the study by competitive 
enrollment in the order in which they presented for 
the study. Patients started treatment within 2  weeks of 
registration and confirmation of eligibility. ASO was 
administered intravenously over 1–2 h as a loading dose 
of 0.32  mg/kg/day for 4  days in week 1 (days 1, 2, 3, 4) 
followed by 0.25  mg/kg/day twice per week (two con-
secutive days) for 5 weeks and then a 2 week rest period 
prior to the initiation of a new cycle for a schedule of 
8 weeks per cycle. This dose and schedule of ASO were 
previously established to be safe in a phase II study in 
advanced melanoma patients [13]. Patients who expe-
rienced any delay in treatment during the cycle were 
not allowed to make up the missed doses, such that no 
cycle was longer than 8 weeks and the required 2-week 
rest period was observed prior to the beginning of a new 
cycle. Treatment was administered on an outpatient basis 
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and continued for a maximum of six cycles not to exceed 
85 daily infusions of ASO in line with the prescribing 
information. Restaging scan by cross sectional imag-
ing was obtained prior to the beginning of a new cycle 
approximately every 8  weeks. Response assessment was 
performed according to the RECIST 1.0 criteria at the 
end of each cycle approximately every 8 weeks. Patients 
who completed or discontinued treatment were followed 
for survival at intervals of approximately 3 months until 
study closure or patient death, whichever occurred first.
Ex vivo and in vitro efficacy testing using cell line 
and patient‑derived xenograft
Short-term in  vitro growth inhibition by cisplatin and 
ASO of TKO-002 cell line derived from a biopsy sample 
of one of the enrolled patients was assessed using MTS 
[(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium)/phenazine 
methosulfate (PMS)] colorimetric assay (Promega, Madison, 
WI) as we previously described [14]. Briefly, exponen-
tially growing TKO-002 cells cultured in 96-well cell 
culture plates were treated by continuous exposure to 
vehicle or increasing concentrations of ASO (0.2–24 μM) 
and cisplatin (2–216 μM). In a separate experiment, fixed 
concentrations of ASO (6  μM) and cisplatin (2.5 and 
10 μM) were tested singly and in combination. The inhib-
itory concentration (IC50) and percent growth inhibi-
tion by fixed doses of the cytotoxic agents was calculated 
using GraphPad Prism software (GraphPad Software, 
Inc. La Jolla, CA).
Ex vivo efficacy testing was conducted under an ani-
mal protocol approved by the Emory University Institu-
tional Animal Care and Use Committee (IACUC) and 
in accordance with guidelines for the humane treatment 
of laboratory animals. Pretreatment tumor biopsy was 
collected from consenting patients prior to initiation of 
treatment with ASO. Tumor samples were obtained by 
image-guided core needle biopsy or by bronchoscopy in 
patients with centrally located tumor. Tissue specimens 
were collected under sterile condition in antibiotic-con-
taining RPMI medium and immediately transplanted as 
2–3 mm3 pieces into subcutaneous pockets on each side 
of the lower back of two 6-week old female NOD SCID 
mice (Harlan Laboratories, Inc. Indianapolis, IN US) [15]. 
Tumors from the first generation of mice were harvested 
after reaching an approximate size of 1.5 cm in diameter 
and directly re-implanted into a new generation of five 
6-week old female athymic nude mice (Harlan Laborato-
ries, Inc. Indianapolis, IN US) for up to five generations. 
Remnant tumor samples (suspended in 10  % DMSO 
plus 10  % FBS containing medium) were cryopreserved 
in liquid nitrogen and kept as a live bank for future use. 
Representative samples from harvested tumors were 
confirmed as human SCLC using standard H&E and 
immunohistochemistry staining with antibodies against 
CD56 (NCMA1), synaptophysin and chromogranin. In 
addition, integrity, relatedness and human origin of the 
PDX were confirmed using short tandem repeat (STR) 
profiling. The profiles of ten core STR markers (TH01, 
D21S11, D5S818, D13S317, D7S820, D16S539, CSF1PO, 
AMEL, vWA, and TPOX) were tested to establish the 
unique profile of each PDX and to show the relatedness 
of different generations of each PDX to one another.
Anti-tumor efficacy of ASO was evaluated in two 
PDX models representative of platinum sensitive (TKO-
005) and platinum refractory (TKO-002) SCLC. Briefly, 
actively growing subcutaneous PDX tumor was har-
vested and immediately implanted into cohorts of nu/
nu mice. Once the tumor volume reached an average size 
of 100 mm3, PDX-bearing mice were matched for tumor 
size and treated in groups of 3–6 animals with vehicle 
(0.9  % NaCl i.p. weekly), cisplatin (3  mg/kg i.p. weekly) 
or ASO (3.75  mg/kg i.p. every other day). In a separate 
experiment we attempted to demonstrate the synergistic 
efficacy of the combination of ASO (7.5 mg/kg i.p. daily) 
and cisplatin (3 mg/kg i.p. weekly) as previously reported 
using conventional models of SCLC [10]. Animal weight 
and tumor growth were measured twice weekly. Tumor 
volume was calculated using external caliper measure-
ment by the formula: 0.5× (length× (width)2). Animals 
were euthanized and harvested tumors were weighed at 
the end of treatment.
Targeted DNA sequencing
SNaPshot multiplex sequencing technique was 
employed to identify TP53 gene mutations and other 
frequently mutated oncogenes in lung cancer includ-
ing AKT1 (c.49G>A), BRAF (c.1397G>T, c.1406G>A/
C/T, c.1789C>G, c.1799T>A), EGFR (c.2156G>A/C, 
c.2369C>T, c.2573T>G, c.2582T>A, exon.19.del, exon.20.
ins), ERBB2 (ins.A775/exon.20.ins), KRAS (c.181C>A/G, 
c.182A>C/G/T, c.183A>C/T, c.34G>A/C/T, c.35G>A/C/T, 
c.37G>A/C/T, c.38G>A/C/T, c.180.181TC>CA), MEK1 
(c.167A>C, c.171G>T, c.199G>A), NRAS (c.181C>A/G, 
c.182A>C/G/T) and PIK3CA (c.1624G>A/C, c.1633G>A/
C,c.3140A>G/T). Harvested tumor samples from the PDX 
were employed for targeted sequencing. Sample prepara-
tion and genetic mutation identification followed previ-
ously described methodologies [16].
Statistical analysis
The clinical study was designed using a MiniMax design 
to test the hypothesis that ASO will achieve an over-
all response rate (ORR) of 20  % in relapsed SCLC. The 
study had 90  % power at an alpha level of 10  % to dis-
tinguish a promising RR of 20  % if the agent is active 
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versus a 5 % ORR if inactive. In the first stage of the study, 
≥1 of 18 eligible patients with an objective response by 
RECIST criteria was required in order to enroll 14 addi-
tional patients to the second stage of the study for a total 
accrual goal of 32 patients. At the end of stage II accrual, 
≤4 of the 32 patients must have achieved an objective 
response for ASO to be deemed active in the relapsed 
SCLC patient population. An alternative endpoint of 
clinical benefit rate (CBR i.e., sum of CR, PR or SD) was 
also pre-specified in the event that the study failed to 
meet its ORR endpoint either at the end of stage I accrual 
or at final analysis. A CBR of 40 % would be considered 
sufficient justification for further evaluation of ASO in 
SCLC. All patients who received any amount of the study 
drug were evaluable for toxicity using the CTCAE ver-
sion 4 criteria. Receipt of at least 75  % of the planned 
dose intensity in cycle 1 was required for a patient to be 
deemed evaluable for efficacy using RECIST criteria 1.1. 
Differences at the end of treatment in mean tumor vol-
ume and mean harvested tumor weights between animal 
groups treated with vehicle, ASO or cisplatin was com-




We enrolled 20 eligible patients including 13 males and 
seven females. Nineteen patients initiated treatment as 
prescribed by protocol. The median age was 63  years. 
Eleven patients had platinum sensitive SCLC (defined as 
disease progression >90  days from the end of frontline 
therapy) and eight patients had known brain metasta-
sis at the time of enrollment on study. The full details of 
patient and tumor characteristics as well as prior thera-
pies are provided in Table 1.
Adverse events
Most patients experienced grade 1 and 2 adverse events. 
The most frequent grade 3 or 4 adverse events are 
detailed in Table  2 and there were no grade 5 adverse 
events recorded on study.
Clinical efficacy
Seventeen patients were evaluable for efficacy as defined 
by the protocol. There were no complete or partial 
responses. The best outcome was stable disease in two 
patients and progressive disease in 15 patients. The 
median time to progression was 7  weeks (1–17  weeks) 
while the median overall survival was 4.5  months 
(2–7  months); 6- and 12-month survival rates were 
30.0 % (12.3, 50.1 %) and 10.0 % (1.7, 27.2 %) respectively. 
Only one of 20 enrolled patients was still alive at the time 
of data analysis. There was no significant association 
between clinical efficacy and patient characteristics. 
However, a non-significant trend was observed toward 
higher risk of death in patients older than 65 years of age 
(HR 2.85; 95 % CI 0.95–8.55; p = 0.061).
Patient‑derived xenografts (PDX)
Nine patients underwent pretreatment tumor biopsy for 
the purpose of generating PDX. Implanted tissue biop-
sies and corresponding PDX and cell lines were serially 
numbered as TKO-001 through TKO-009. We success-
fully generated PDXs from 5 of 9 patients for a take rate 
of 56  %. The mean and median time to PDX develop-
ment post initial direct implant from the patient biopsy 
were 172 (±114) days and 135 days (range 49–335 days), 
respectively. PDXs were eventually propagated across five 
generations of mice. There was a progressive decrease in 
the interval of time from implant to tumor development 
with serial passage.
PDX purity and relatedness
The PDX preserved the characteristic histopathologic 
features of human SCLC with serial passage (Fig.  1; 
Additional file 1: Fig. S1). PDX purity across the first two 
generations for each of the five PDXs was authenticated 
Table 1 Patient characteristics and summary of treatment 
efficacy
a Platinum/etoposide; platinum etoposide/XRT, platinum/etoposide/GDC-049
b Topotecan, oral etoposide, platinum/irinotecan, platinum/etoposide, 
topotecan/aflibercept; gemcitabine, paclitaxel
c Platinum etoposide, platinum/irinotecan, topotecan, irinotecan
d Irinotecan
Variable Level N = 20 %
Gender F 7 35.0
M 13 65.0
Race White 16 80.0
Black 4 20.0
Age (years) Mean 63.40 (10.67)
Median 63 (48–84)
Age (years) <65 10 50.0
≥65 10 50.0
ECOG performance status 0 2 10
1 13 65
2 5 25




Best response PD 15 88.2
SD 2 11.8
Time to progression (TTP) Mean 6.26 (3.9)
Median 7 (1–17)
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using STR profiling (Fig. 2; Table 3). Due to variable rate 
of growths of the PDX, we used samples from the first 
two generations of each PDX for STR profiling. Further-
more, targeted sequencing of the harvested PDX using a 
standard clinical NexGen sequencing platform employed 
at our institution recapitulated the genetic characteristics 
of human SCLC with universal alterations in TP53 gene. 
There was also relative stability of the genomic altera-
tions across tumor generations (Table  4). Additionally, 
re-implantation of representative tumor samples that had 
been stored in liquid nitrogen for more than 2 years led 
to successful tumor regrowth in mice. Detailed clinical 
information of nine patients who underwent biopsy for 
PDX generation and outcomes are presented in Table 5.    
In vitro and ex vivo efficacy of ASO and cisplatin in PDXs
We were successful in establishing the optimal condition 
for exponential growth of cell lines obtained from patient 
biopsy for in vitro work from TKO-002 only. Both cispl-
atin and ASO demonstrated modest in  vitro cytotoxic-
ity against TKO-002 with IC50 concentrations of 11.25 
and 3.08 μM respectively (Fig. 3, top and middle panel). 
The combination of ASO and cisplatin, however, did not 
show any additive or synergistic effect against TKO-002 
cell line in vitro (Fig. 3, bottom panel).
Ex vivo efficacy of ASO and cisplatin was assessed in 
two representative PDXs, TKO-002 and TKO-005, gen-
erated using biopsy samples from patients with plati-
num refractory and platinum sensitive relapsed SCLC, 
respectively. The PDX samples employed for ex  vivo 
testing were the second generation PDX for each case. 
The source patients for the two PDXs were evaluable for 
efficacy assessment following treatment with ASO on the 
human clinical trial. PDX-bearing animals were treated 
with vehicle (no expected effect), cisplatin (to model plat-
inum resistance or sensitivity) and ASO (to replicate clin-
ical efficacy in the patients). Compared to vehicle-treated 
animals, there was no significant inhibition of TKO-
002 PDX tumor growth by cisplatin (p =  0.42) or ASO 
(p  =  0.48), and no significant difference in harvested 
tumor weights between vehicle and ASO-treated tumors 
(p = 0.33) at the end of treatment (Fig. 4). Of note, this 
PDX was generated from a patient with platinum refrac-
tory disease.
Contrarily, while ASO showed no significant efficacy in 
terms of tumor growth inhibition (p = 0.40) or harvested 
tumor weight (p  =  0.46) against TKO-005 PDX, there 
was significant antitumor effect of cisplatin against this 
PDX, which was generated from a patient with platinum 
sensitive disease, as indicated by the significant reduc-
tion in harvested tumor weight (p = 0.04) with a trend in 
reduced tumor volume (p = 0.05) at the end of treatment 
(Fig.  5). In order to test whether the PDX model could 
predict efficacy of other agents beyond cisplatin, we also 
evaluated the in  vivo efficacy of ON.01910.Na (rigos-
ertib), a novel agent, targeting polo-like kinase 1 (PLK1), 
which was previously identified as a promising target in 
SCLC [17]. When tested along with cisplatin and ASO in 
this platinum-sensitive model, we observed that the effi-
cacy of the PLK1 inhibitor to be comparable to cisplatin 
in this PDX model (Fig. 5).
The combination of ASO and cisplatin was shown to 
be synergistic in preclinical models of SCLC and other 
cancers [10, 18–20]. We attempted to replicate this 
observation in our SCLC PDX model in order to further 
explore whether this strategy holds sufficient promise to 
warrant future clinical testing. There was significant tox-
icity of single agent ASO and its combination with cis-
platin (Fig. 6) at the dose (7.5 mg/kg i.p daily) previously 
reported to be effective in SCLC xenograft model [10]. 
The reduced dose (3.75  mg/kg i.p) was better tolerated 
but did not have any significant effect on tumor growth 
as a single agent and failed to potentiate cisplatin in this 
PDX model of SCLC (Fig. 6).
Discussion
We report the outcome of a prospective co-clinical trial of 
ASO in relapsed SCLC patients and corresponding PDX 
models. ASO is an effective therapy in acute promyelo-
cytic leukemia (APL) [21, 22] and has been shown to be 
active in several other cancer types [13]. Despite findings 
from preclinical studies of in vitro and in vivo activity of 
ASO against SCLC, which suggested a high potential for 
Table 2 List and frequency of grade ≥3 adverse events
Adverse event N (%) Grade
Dyspnea 1 (4.5) 3
Anemia 1 (4.5) 3
Back pain 1 (4.5) 3
Elevated creatinine 1 (4.5) 3
Facial edema around eyes 1 (4.5) 3
Generalized weakness 1 (4.5) 3
Hyperbilirubinemia 2 (9) 3
Hyperglycemia 1 (4.5) 3
Hypoalbuminemia 2 (9) 3
Hypocalcemia 1 (4.5) 3
Hyponatremia 1 (4.5) 3
Hypophosphatemia 1 (4.5) 3
Increased alkaline phosphatase 1 (4.5) 3
Increased lipase 1 (4.5) 3
Leukopenia 2 (9) 3
Neutrophil count decreased 1 (4.5) 3
Pleural effusion 1 (4.5) 3
Hyperbilirubinemia 1 (4.5) 4
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Fig. 1 Subcutaneous growth of patient‑derived xenograft in a SCID mouse host just prior to euthanasia. Harvested tumor from bilateral subcutane‑
ous pockets; 3 × 3 mm sized sections were immediately propagated to the next generation of mice through implantation into subcutaneous pock‑
ets over the hind legs of the mice without in vitro manipulation (top panel). Histopathologic confirmation of small cell lung carcinoma histology by 
hematoxylin and eosin stain (X400) and immunohistochemistry for neuroendocrine differentiation showing intense diffusely positive staining for 
CD56 (middle panel), moderately intense staining for synaptophysin and focal areas of weakly positive chromogranin A staining (bottom panel)
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clinical benefit of this agent in SCLC, [10–12], we could 
not demonstrate any significant anticancer efficacy of 
ASO in relapsed SCLC patients treated as part of this 
co-clinical trial. PDX models are becoming increasingly 
recognized as superior to traditional xenograft tumor 
models in faithfully representing the behavior of cancer 
in patients. We therefore incorporated PDX generation 
as a component of this clinical trial. Our success rate in 
establishing PDXs of 56 % compared well to the reported 
experience of other groups using circulating tumor cells 
or similar tissue biopsy techniques as we employed in 
this study [23–25]. This co-clinical trial approach allowed 
us to further interrogate the possible reasons for the fail-
ure to observe meaningful clinical benefit in the clinical 
trial participants despite the prediction of clinical efficacy 
of ASO by experiments in SCLC cell lines and traditional 
xenografts [10–12]. We, however, observed a consist-
ency in outcome between patients and the corresponding 
representative PDX models and in the TKO-002 SCLC 
cell line, which was generated from a platinum refrac-
tory patient. The estimated IC50 concentration of cispl-
atin against this line of 11.25 μM is several folds higher 
than the range of 2–6.5 μM that is the achievable mean 
plasma concentration of free unbound and total cisplatin 
in patients [26, 27]. This result supports the expectation 
of platinum resistance in this cell line. We were unable 
to generate stably proliferating cell line for in vitro rep-
lication of platinum sensitivity in TKO-005, which was 
obtained from a patient with platinum sensitive disease. 
The estimated IC50 for ASO in TKO-002 of 3.08  μM is 
within the range of 3–7  μM achievable in plasma of 
patients [21, 28, 29]; and is comparable to the IC50 con-
centrations in APL cell lines [28]. However, human PK 
study showed a rapid clearance of ASO from the plasma 
within hours suggesting that intermittent dosing is 
suboptimal for maintaining the required drug level in 
patients. Overall, our data provide a reasonable ground 
to contend that prior screening of ASO using a PDX 
model along with or in place of the standard cell-derived 
xenograft could have provided a better hint of the likely 
clinical result thereby informing a reconsideration or 
redesign of the clinical trial. Our data supports the con-
clusion that failure to demonstrate clinical benefit both 
in terms of response or durable disease control is most 
likely due to a true lack of activity of ASO in unselected 
relapsed SCLC patients.
Table 3 STR profiling of PDX tumor samples
PDX TH01 D21S11 D5S818 D13S317 D7S820 D16S539 CSF1PO AMEL vWA TPOX
TKO‑001_P1 7 7 29 29 7 7 11 11 10 11 11 12 12 12 X Y 18 18 11 11
TKO‑001_P2 7 7 29 29 7 7 11 11 10 11 11 12 12 12 X Y 18 18 11 11
TKO‑002_P1 7 9.3 27 31 13 13 11 12 8 11 9 12 11 11 X X 16 17 9 9
TKO‑002_P2 7 9.3 27 31 13 13 11 12 8 11 9 12 11 11 X X 16 17 9 9
TKO‑003_P1 7 7 29 29 11 12 11 11 10 10 9 9 7 13 X X 16 16 9 11
TKO‑003_P2 7 7 29 29 11 12 11 11 10 10 9 9 7 13 X X 16 16 9 11
TKO‑005_P1 8 9.3 29 31 12 12 12 12 10 10 8 9 10 12 X X 19 19 8 9
TKO‑005_P2 8 9.3 29 31 12 12 12 12 10 10 8 9 10 12 X X 19 19 8 9
TKO‑008_P2 6 6 30 31 13 13 10 10 11 12 9 9 12 12 X X 17 18 8 8
TKO‑008_P1 6 6 30 31 13 13 10 10 11 12 9 9 12 12 X X 17 18 8 8
Table 4 Specific genetic alterations in TP53 gene detected in the five SCLC PDXs
PDX TP53 alteration COSMIC ID# Remarks
TKO‑001 c.422G>A[p.Cys141Tyr] COSM131470 Missense mutation
TKO‑002 c.488A>G[p.Tyr163Cys] COSM10808 Listed in COSMIC and dbSNP (rs148924904), evidence in COSMIC for being somatic
TKO‑003 c.913A>T[p.Lys305Ter] COSM43773 Stop (Ter) Hemizygous, deletion of one copy
TKO‑005 c.488A>G[p.Tyr163Cys] COSM10808 Listed in COSMIC and dbSNP (rs148924904), evidence in COSMIC for being somatic
TKO‑008 c.892G>T[p.Glu298Ter] COSM10710 Stop (Ter) 80 % of reads
(See figure on previous page.) 
Fig. 2 Electropherogram showing unique profile of each of five different PDX models generated from SCLC. Note the identical STR profile of tumor 
samples harvested from animals bearing first generation (passage 1) and second generation (passage 2) PDX
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Other possible explanations for the lack of benefit 
include the fact that we employed an intermittent sched-
ule of drug administration over 2–4  days in order to 
minimize hematologic toxicity unlike in APL patients 
where ASO is administered as a daily continuous regi-
men. This dosing schedule was previously established as 
the safe dose in patients with solid malignancies [13] as 
opposed to the continuous dosing employed in patients 
with APL [28]. While this can be overcome by the abil-
ity of APL cell to trap ASO intracellularly, it is unknown 
Fig. 3 SCLC cell line derived directly from a tumor biopsy speci‑
men employed for the generation of TKO‑002 PDX was employed 
for in vitro cytotoxicity assessment. TKO‑002 cells were seeded in 
96‑well plates and allowed to grow overnight. Exponentially growing 
cells were treated the next day with vehicle or serially increasing 
concentrations of cisplatin (2–216 μM) and ASO (0.2–24 μM). After 
72 h of continuous drug exposure, cell numbers were estimated 
using MTS assay. IC50 concentration was estimated from the growth 
inhibition using GraphPad prism software. The IC50 concentration for 
cisplatin (top panel) and ASO (middle panel) was estimated at 11.25 
and 3.08 μM, respectively. There was no demonstrable additive or 
synergistic effect of the combination of ASO (6 μM) and cisplatin (2.5 










































































Fig. 4 Efficacy of ASO (3.75 mg/kg i.p. every other day) and cisplatin 
(3 mg/kg i.p. weekly) was tested in TKO‑002, a PDX model of platinum 
refractory SCLC. Tumor volume (mm3) and body weight of animals 
were measured at least twice weekly while on treatment. There was 
no significant tumor growth inhibition by ASO (*p = 0.48) or cisplatin 
(**p = 0.42) in comparison to vehicle‑treated control animals at 
the end of the treatment period (top). There was also no significant 
difference in the harvested tumor weights from animals treated with 
ASO compared to control animals treated with vehicle (*p = 0.33) 
(middle). There was no significant increase in toxicity (measured by 
body weight of the animals) with active therapy in comparison to 
controls (bottom)













































































Fig. 5 To assess the efficacy of ASO and cisplatin (CDDP) in TKO‑005, a PDX model of platinum sensitive SCLC, animals were treated and monitored 
for tumor growth and body weight as described in Fig. 4. In addition, a matching group of tumor‑bearing mice was treated with rigosertib (250 mg/
kg i.p. daily). At the end of the treatment period, there was no significant reduction in tumor volume in animals treated with ASO (*p = 0.40) but 
a significant reduction was achieved with cisplatin (**p = 0.048) and a strong trend toward reduced tumor volume was noted with rigosertib 
(p = 0.058) in comparison to vehicle‑treated control animals. Similarly, harvested tumor weights were significantly lower from animals treated with 
cisplatin (**p = 0.04) and rigosertib (p = 0.038) but not from animals treated with ASO (*p = 0.46) in comparison to control animals. There was no 
significant increase in toxicity as measured by body weight of the animals on active therapy in comparison to controls. Furthermore, rigosertib (ON‑
01910.Na) efficacy was comparable to cisplatin both in terms of growth inhibition (p = 0.24) and harvested tumor weights (p = 0.32) at the end of 
treatment
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whether other cancer cells possess the same capability 
[28]. Although the relative reduction in dose intensity 
in our study in comparison to the dose and schedule 
employed for APL patients, where the agent is particu-
larly effective could be one of the factors contribut-
ing to the negative result of the clinical trial. However, 
treatment of PDX-bearing mice with the same dose and 
schedule of ASO as was shown in earlier studies to have 
promising efficacy in conventional xenograft models 
failed to inhibit tumor growth [10, 11]. This suggests that 
the lack of clinical efficacy reflects the inadequacy of the 
traditional xenograft model to accurately predict out-
come in patients. Additionally, ASO as a differentiating 
agent is expected to have greater effect on the undifferen-
tiated tumor compartment rather than the entire tumor 
bulk. The undifferentiated compartment represents a 
smaller fraction of the total tumor bulk in solid tumors 
as compared to APL. Nonetheless, SCLC tends to have a 
high proportion of undifferentiated cells. We confirmed 
this by testing for expression of CD133 and CD87, which 
are established markers of undifferentiated cells in our 
PDX samples, and observed high expression of both of 
these markers across multiple generations of PDX (Addi-
tional file 1: Fig. S1). It is plausible that ASO may be more 
efficacious when combined with a cytotoxic agent that 
targets the remaining differentiated tumor compartment. 
Consistent with this expectation, Zheng et al. showed in 
preclinical models using the H841 SCLC cell line xeno-
graft that the combination of ASO and cisplatin is much 
more potent than either agent alone [10]. However, we 
were unable to replicate this synergistic interaction using 
our SCLC PDX model in part due to excessive toxicity of 
the combination of cisplatin and ASO at doses required 
for clinical activity.
The concordance of the limited clinical efficacy of ASO 
and the lack of antitumor efficacy in the PDX model may 
be agent specific and thus may not be generalizable to 
other agents with different mechanism of action. Moreo-
ver, inherent genetic heterogeneity in tumors may limit 
concordance of PDX and clinical outcome since PDXs 
are generated using biopsy samples obtained from lim-
ited sites of tumor involvement. It is anticipated that 
these reasonable grounds of skepticism will be further 
addressed in future co-clinical trials and with increased 
use of the PDX model as a screening platform. How-
ever, we have employed some of the PDX models gener-
ated from this co-clinical trial to screen other classes of 
anticancer compounds including rigosertib, an inhibitor 
of PLK-1, which was previously shown to have potent 
in  vitro activity against SCLC [17] as well as BDA-366, 
a novel BH4-mimetic Bcl2 inhibitor, with which we 
observed significant antitumor effect [30]. Furthermore, 
translational studies conducted by other groups but not 
as part of a prospective co-clinical trial also showed that 
SCLC PDX models replicate clinical activity of stand-
ard chemotherapy agents [31–33] and showed greater 
concordance with clinical experience in comparison 
to results obtained from in  vitro and cell line derived 
Fig. 6 Efficacy of ASO and cisplatin (CDDP) singly and in combina‑
tion was tested in TKO‑002, a PDX model of platinum refractory 
SCLC. Kaplan–Meier survival curves for animal groups treated with 
vehicle, ASO (7.5 mg/kg i.p. daily), cisplatin (3 mg/kg i.p. weekly) and 
the combination of ASO plus cisplatin. There was significant toxicity 
with rapid death of mice treated with ASO alone or in combination 
with cisplatin (top). A reduced dose of ASO (3.75 mg/kg every other 
day) was better tolerated but showed negligible efficacy and failed 
to potentiate the minimal growth inhibition achieved by cisplatin 
(3 mg/kg i.p. weekly) in this PDX model derived from a patient with 
platinum resistant SCLC (middle and bottom panel)
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xenograft experiments [34]. While it may be premature 
at this point to generalize that PDX model should be the 
gold standard platform for preclinical screening of novel 
agents against SCLC, it is safe to suggest that PDX model 
should be a component of the systematic preclinical 
screening strategy for novel agents against SCLC in order 
to improve the chances of clinical success.
Conclusions
We report a prospectively designed co-clinical trial of 
anticancer agent therapy in SCLC patients and PDX mod-
els. While ASO failed to demonstrate meaningful clinical 
activity, the PDX models generated in the context of this 
study provide great insight into optimal platform for pre-
clinical testing of novel therapeutic strategies in SCLC.
Abbreviations
SCLC: small cell lung cancer; ASO: arsenic trioxide; PDX: patient‑derived xeno‑
graft; ULN: upper limit of normal; SD: stable disease; PR: partial response; CBR: 
clinical benefit rate.
Authors’ contributions
Study design TKO, ZC, SSR, FRK. Patient enrolment on study TKO, RMS, NFS, SP, 
RNP, SSR, FRK. Tumor biopsy collection GZ, TKO, HSK, RMS, RB. Ex vivo experi‑
ments TKO, GZ, GLS, XD, SS, Genomic studies MRR, GLS. Data analysis and 
interpretation: all authors. Manuscript writing: all authors. All authors read and 
approved the final manuscript.
Author details
1 Department of Hematology & Medical Oncology, Emory University School 
of Medicine, Winship Cancer Institute, 1365C Clifton Road, NE, Suite C3080, 
Atlanta, GA 30322, USA. 2 Department of Radiology, Division of Interventional 
Radiology, Emory University School of Medicine, Winship Cancer Institute, 
Atlanta, GA 30322, USA. 3 Winship Cancer Institute, Atlanta, GA 30322, USA. 
4 Department of Medicine, Division of Interventional Pulmonology, Winship 
Cancer Institute, Atlanta, GA 30322, USA. 5 Department of Biostatistics, Rollins 
School of Public Health and Biostatistics Shared Resource, Winship Cancer 
Institute, Atlanta, GA 30322, USA. 6 Department of Radiation Oncology, Win‑
ship Cancer Institute, Atlanta, GA 30322, USA. 7 Department of Pathology, 
Winship Cancer Institute, Atlanta, GA 30322, USA. 
Acknowledgements
This study was supported in part by NIH/NCI 5K23CA164015 Grant award (PI: 
TK Owonikoko) and the Winship‑Kennedy pilot Grant award from the Winship 
Cancer Institute of Emory University (PI: TK Owonikoko). Research reported in 
this publication was also supported in part by the Biostatistics and Bioinfor‑
matics Shared resource of Winship Cancer Institute of Emory University and 
NIH/NCI under award number P30CA138292. The content is solely the respon‑
sibility of the authors and does not necessarily represent the official views of 
the National Institutes of Health.
Additional file
Additional file 1: Figure S1. We employed immunohistochemistry to 
assess the level of expression of CD133 (1:100 dilution; mouse monoclonal 
antibody; Cat# MAB4310, EMD Millipore Corporation, Billerica, MA USA) 
and CD87 (1:100 dilution; rabbit polyclonal antibody; Cat# PA5‑15478, 
Invitrogen, Thermo Fisher Scientific, Rockford, IL 61105 USA) in representa‑
tive tumor tissues harvested from the first three generations of the five 
PDXs. There was weak to moderate degree of expression as measured 
by immunoscore (product of staining intensity and percent cell staining) 
with comparable expression between the five SCLC PDXs and across the 
three generations of each PDX.
ASO was generously provided free to all patients enrolled on study by 
Teva Pharmaceuticals. Teva pharmaceutical reviewed the draft manuscript. 
The study was registered at http://www.clinicaltrials.gov (NCT01470248). The 
corresponding author had full access to the entire data and vouch for the 
integrity of the data presented in the manuscript. All authors reviewed and 
approved the final draft of the manuscript. All authors have read the journal’s 
policy on conflicts of interest, read the journal’s authorship agreement and 
have no potential conflicts of interest to disclose.
We thank Anthea Hammond, Ph.D. for editorial assistance with proof read‑
ing the manuscript and helpful suggestion on data presentation.
Competing interests
The authors declare that they have no competing interests.
Received: 4 January 2016   Accepted: 12 April 2016
References
 1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 
2014;64:9–29.
 2. Kalemkerian GP. Chemotherapy for small‑cell lung cancer. Lancet Oncol. 
2014;15:13–4.
 3. Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. 
Semin Oncol. 2014;41:133–42.
 4. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, 
Spigel DR, Dudek AZ, Shah C, et al. Phase II study of amrubicin as second‑
line therapy in patients with platinum‑refractory small‑cell lung cancer. J 
Clin Oncol. 2010;28:2598–603.
 5. Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, 
Ramalingam SS. A systematic analysis of efficacy of second‑line chemo‑
therapy in sensitive and refractory small‑cell lung cancer. J Thorac Oncol. 
2012;7:866–72.
 6. Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, Aboody 
KS. Identification of uPAR‑positive chemoresistant cells in small cell lung 
cancer. PLoS One. 2007;2:e243.
 7. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi 
G, Fabbri A, Andriani F, Tinelli S, et al. Highly tumorigenic lung cancer 
CD133+ cells display stem‑like features and are spared by cisplatin treat‑
ment. Proc Natl Acad Sci USA. 2009;106:16281–6.
 8. Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, Ichihara E, 
Yamane H, Tanimoto M, Kiura K. Subpopulation of small‑cell lung cancer 
cells expressing CD133 and CD87 show resistance to chemotherapy. 
Cancer Sci. 2013;104:78–84.
 9. Zheng CY, Lam SK, Li YY, Ho JC. Arsenic trioxide‑induced cytotoxicity in 
small cell lung cancer via altered redox homeostasis and mitochondrial 
integrity. Int J Oncol. 2015;46:1067–78.
 10. Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC. Combination of arsenic 
trioxide and chemotherapy in small cell lung cancer. Lung Cancer. 
2013;82:222–30.
 11. Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, 
Shoshan MC, Pahlman S. Arsenic trioxide is highly cytotoxic to small cell 
lung carcinoma cells. Mol Cancer Ther. 2009;8:160–70.
 12. Yang MH, Zang YS, Huang H, Chen K, Li B, Sun GY, Zhao XW. Arsenic 
trioxide exerts anti‑lung cancer activity by inhibiting angiogenesis. Curr 
Cancer Drug Targets. 2014;14:557–66.
 13. Tarhini AA, Kirkwood JM, Tawbi H, Gooding WE, Islam MF, Agarwala SS. 
Safety and efficacy of arsenic trioxide for patients with advanced meta‑
static melanoma. Cancer. 2008;112:1131–8.
 14. Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho 
GH, Chen Z, Kim S, Strychor S, Christner SM, et al. Poly (ADP) ribose 
polymerase enzyme inhibitor, veliparib, potentiates chemotherapy 
and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 
2014;3:1579–94.
 15. Rubio‑Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio‑Donahue C, 
Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, et al. An 
in vivo platform for translational drug development in pancreatic cancer. 
Clin Cancer Res. 2006;12:4652–61.
Page 14 of 14Owonikoko et al. J Transl Med  (2016) 14:111 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 16. Su Z, Dias‑Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung 
CH, Massion PP, Vnencak‑Jones CL, Iafrate AJ, Pao W. A platform for rapid 
detection of multiple oncogenic mutations with relevance to targeted 
therapy in non‑small‑cell lung cancer. J Mol Diagn. 2011;13:74–84.
 17. Wildey G, Chen Y, Lent I, Stetson L, Pink J, Barnholtz‑Sloan JS, Dowlati A. 
Pharmacogenomic approach to identify drug sensitivity in small‑cell lung 
cancer. PLoS One. 2014;9:e106784.
 18. Li H, Zhu X, Zhang Y, Xiang J, Chen H. Arsenic trioxide exerts synergistic 
effects with cisplatin on non‑small cell lung cancer cells via apoptosis 
induction. J Exp Clin Cancer Res. 2009;28:110.
 19. Zhang N, Wu ZM, McGowan E, Shi J, Hong ZB, Ding CW, Xia P, Di W. 
Arsenic trioxide and cisplatin synergism increase cytotoxicity in human 
ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 
2009;100:2459–64.
 20. Nakaoka T, Ota A, Ono T, Karnan S, Konishi H, Furuhashi A, Ohmura Y, 
Yamada Y, Hosokawa Y, Kazaoka Y. Combined arsenic trioxide‑cisplatin 
treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell 
Oncol. 2014;37:119–29.
 21. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, 
Yang KQ, et al. Use of arsenic trioxide (As2O3) in the treatment of acute 
promyelocytic leukemia (APL): II. clinical efficacy and pharmacokinetics in 
relapsed patients. Blood. 1997;89:3354–60.
 22. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso 
D, DeBlasio A, Gabrilove J, Scheinberg DA, et al. Complete remission after 
treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J 
Med. 1998;339:1341–8.
 23. Anderson WC, Boyd MB, Aguilar J, Pickell B, Laysang A, Pysz MA, 
Bheddah S, Ramoth J, Slingerland BC, Dylla SJ, Rubio ER. Initiation and 
characterization of small cell lung cancer patient‑derived xenografts 
from ultrasound‑guided transbronchial needle aspirates. PLoS One. 
2015;10:e0125255.
 24. Leong TL, Marini KD, Rossello FJ, Jayasekara SN, Russell PA, Prodanovic 
Z, Kumar B, Ganju V, Alamgeer M, Irving LB, et al. Genomic characterisa‑
tion of small cell lung cancer patient‑derived xenografts generated from 
endobronchial ultrasound‑guided transbronchial needle aspiration 
specimens. PLoS One. 2014;9:e106862.
 25. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polan‑
ski R, Burt DJ, Simpson KL, Morris K, et al. Tumorigenicity and genetic 
profiling of circulating tumor cells in small‑cell lung cancer. Nat Med. 
2014;20:897–903.
 26. Urien S, Lokiec F. Population pharmacokinetics of total and 
unbound plasma cisplatin in adult patients. Br J Clin Pharmacol. 
2004;57:756–63.
 27. Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, 
Monjanel‑Mouterde S, Baciuchka‑Palmaro M, Dupuis C, Yang C, et al. 
Therapeutic drug monitoring for dose individualization of cisplatin in 
testicular cancer patients based upon total platinum measurement in 
plasma. Ther Drug Monit. 2006;28:532–9.
 28. Chendamarai E, Ganesan S, Alex AA, Kamath V, Nair SC, Nellickal AJ, Janet 
NB, Srivastava V, Lakshmi KM, Viswabandya A, et al. Comparison of newly 
diagnosed and relapsed patients with acute promyelocytic leukemia 
treated with arsenic trioxide: insight into mechanisms of resistance. PLoS 
One. 2015;10:e0121912.
 29. Fox E, Razzouk BI, Widemann BC, Xiao S, O’Brien M, Goodspeed W, Rea‑
man GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC. Phase 1 trial and 
pharmacokinetic study of arsenic trioxide in children and adolescents 
with refractory or relapsed acute leukemia, including acute promyelo‑
cytic leukemia or lymphoma. Blood. 2008;111:566–73.
 30. Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G, Sica GL, Ding C, Zhou 
J, Magis AT, et al. Small‑molecule Bcl2 BH4 antagonist for lung cancer 
therapy. Cancer Cell. 2015;27:852–63.
 31. Nemati F, Daniel C, Arvelo F, Legrier ME, Froget B, Livartowski A, Assayag F, 
Bourgeois Y, Poupon MF, Decaudin D. Clinical relevance of human cancer 
xenografts as a tool for preclinical assessment: example of in vivo evalu‑
ation of topotecan‑based chemotherapy in a panel of human small‑cell 
lung cancer xenografts. Anticancer Drugs. 2010;21:25–32.
 32. Poupon MF, Arvelo F, Goguel AF, Bourgeois Y, Jacrot M, Hanania N, Arria‑
gada R, Le Chevalier T. Response of small‑cell lung cancer xenografts to 
chemotherapy: multidrug resistance and direct clinical correlates. J Natl 
Cancer Inst. 1993;85:2023–9.
 33. Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, 
Poupon MF. Distinctive potentiating effects of cisplatin and/or ifosfamide 
combined with etoposide in human small cell lung carcinoma xeno‑
grafts. Clin Cancer Res. 2000;6:2075–86.
 34. Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, 
Rudin CM. DNA methylation in small cell lung cancer defines distinct dis‑
ease subtypes and correlates with high expression of EZH2. Oncogene. 
2015;34:5869–78.
